凝血因子ⅡG20210A突变在布加综合征和门静脉血栓形成中的意义  

Significance of factor Ⅱ G20210A mutation in Budd-Chiari syndrome and portal vein thrombosis

作　　者：张文文[1] 祁兴顺[1] 郭晓钟[1] 

机构地区：[1]沈阳军区总医院消化内科,沈阳110016

出　　处：《临床肝胆病杂志》2015年第2期310-314,共5页Journal of Clinical Hepatology

摘　　要：大量研究发现凝血因子ⅡG20210A突变与布加综合征和门静脉血栓形成有关。介绍了凝血因子Ⅱ及凝血因子ⅡG20210A突变,回顾了有关凝血因子ⅡG20210A突变对血栓形成的影响,并对凝血因子ⅡG20210A突变的患病率进行了分析,着重总结了凝血因子ⅡG20210A突变与门静脉血栓和布加综合征的关系。认为凝血因子ⅡG20210A突变在一定程度上增加了门静脉血栓和布加综合征的风险。但凝血因子ⅡG20210A突变在中国患者中的患病率极低,其也许并不足以作为中国门静脉血栓和布加综合征的病因。Budd -Chiari syndrome （BCS） is characterized by the hepatic outflow obstruction from the small hepatic vein to the superior he- patic inferior vena cava. Portal vein thrombosis （PVT） refers to the development of thrombosis in the main portal vein, with or without thrombosis in the superior mesenteric or splenic vein. A large number of studies have shown that prothrombin （factorⅡ, 172） G20210A muta- tion is related to BCS and PVT. F2 and its G20210A mutation are introduced, the effect of F2 G20210A mutation on thrombosis is reviewed, and the prevalence of F2 G20210A mutation in China is analyzed. An attempt is made to focus on the association of F2 G20210A mutation with PVT and BCS. It is believed that F2 G20210A mutation to some extent increases the risk for PVT and BCS. However, the prevalence of F2 G20210A mutation is extremely low in the Chinese population. Thus, this mutation may not be regarded as the cause of PVT and BCS in China.

关 键 词：BUDD-CHIARI综合征 门静脉 静脉血栓形成 凝血酶原 突变 综述 

分 类 号：R575[医药卫生—消化系统]